- Home
- HCM vs DYN Comparison
HCM vs DYN Comparison
Compare HCM & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- DYN
- Stock Information
- Founded
- HCM 2000
- DYN 1984
- Country
- HCM Hong Kong
- DYN United States
- Employees
- HCM N/A
- DYN N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- DYN Medicinal Chemicals and Botanical Products
- Sector
- HCM Health Care
- DYN Health Care
- Exchange
- HCM Nasdaq
- DYN Nasdaq
- Market Cap
- HCM 2.3B
- DYN 2.6B
- IPO Year
- HCM N/A
- DYN 2020
- Fundamental
- Price
- HCM $16.11
- DYN $14.01
- Analyst Decision
- HCM Hold
- DYN Strong Buy
- Analyst Count
- HCM 1
- DYN 10
- Target Price
- HCM $19.00
- DYN $50.78
- AVG Volume (30 Days)
- HCM 71.4K
- DYN 2.1M
- Earning Date
- HCM 03-19-2025
- DYN 03-04-2025
- Dividend Yield
- HCM N/A
- DYN N/A
- EPS Growth
- HCM N/A
- DYN N/A
- EPS
- HCM N/A
- DYN N/A
- Revenue
- HCM $610,806,000.00
- DYN N/A
- Revenue This Year
- HCM N/A
- DYN N/A
- Revenue Next Year
- HCM $15.89
- DYN N/A
- P/E Ratio
- HCM N/A
- DYN N/A
- Revenue Growth
- HCM N/A
- DYN N/A
- 52 Week Low
- HCM $12.84
- DYN $13.07
- 52 Week High
- HCM $21.92
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- HCM 68.69
- DYN 37.85
- Support Level
- HCM $13.58
- DYN $13.59
- Resistance Level
- HCM $13.96
- DYN $14.50
- Average True Range (ATR)
- HCM 0.31
- DYN 0.98
- MACD
- HCM 0.34
- DYN 0.32
- Stochastic Oscillator
- HCM 89.84
- DYN 22.90
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.